Impact of Balanced Crystalloid and Colloid Infusion on Haemostasis in Healthy Male Volunteers

Impact of Infusion of Balanced Crystalloid and Colloid Solutions on Haemostasis in Healthy Male Volunteers- a Randomized Controlled Crossover Trial

The project focuses on perioperative bleeding that requires transfusion of blood products and supplementation of intravascular volume with crystalloids and colloids. The implemented fluid therapy affects coagulation and fibrinolysis, depending on the type of fluid used in an intravenous infusion. Massive haemorrhage significantly impacts the perioperative period and postoperative quality of life and requires individualized therapy, rending the ongoing project relevant from the perspective of the patients.

Study Overview

• Status: Active, not recruiting
• Conditions: Perioperative Hemorrhage; Dilutional Coagulopathy
• Intervention / Treatment: Diagnostic test: Standard laboratory coagulation tests and rotational thromboelastometry measurements

Detailed Description

Perioperative bleeding is a complication that significantly affects postoperative morbidity and quality of life and increases the patient's risk of death. Massive hemorrhage requires individualized therapy, preferably based on international recommendations. It is necessary to transfuse blood and blood products (red blood cells, freshly frozen plasma, platelets, concentrates of coagulation factors) with simultaneous rational supplementation of the intravascular space using crystalloids and colloids. Usually, these are large volumes that are infused over a short time. Proceedings in the operating room and the intensive care unit environment should stabilize the patient's general condition with the lowest possible risk of complications.

However, it has been shown that transfusions are not free from side effects. Transfusions may result not only from "classic" post-transfusion complications (allergic reactions, haemolytic reactions, infections, electrolyte disturbances) but also from iatrogenically generated disorders in the circulatory system (fluid overload), respiratory ( acute lung injury), and hemostasis (risk of hypercoagulability). It is also known that uncontrolled and unbalanced fluid therapy per se may additionally affect the haemodynamic state, haemostasis, and the immune system.

Thromboelastometry (thromboelastography) is becoming the standard of perioperative haemostasis monitoring. It has been documented that it provides more reliable data than standard laboratory tests, such as fibrinogen concentration, activated clotting time (ACT), kaolin-kephalin (aPTT), prothrombin (PT), or INR index. The test can be performed as the so-called point-of-care test (POC), which reduces the waiting time for the result and facilitates goal-directed therapy.

Little is known about the effects of fluid infusion on physiological haemostasis in healthy subjects who do not have a prior bleeding disorder and who are infused with fluids similarly to resuscitation in massive bleeding. Only singular studies in international literature attempted to answer this vital question. Still, the regular progress in the field of fluid therapy makes the obtained data less and less valuable in clinical practice.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Poland
  • Silesia
    • Katowice, Silesia, Poland, 40-752
      • Department of Anaesthesiology and Intensive Care, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 30 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy male volunteers aged 18-30 years
• The American Society of Anaesthesiologists Physical Status (ASA PS) I risk class
• Must be able to give informed consent

Exclusion Criteria:

• Female sex
• Blood type O
• A positive history of any acute diseases in the last four weeks
• Chronic diseases
• Any diagnosed haemostatic disorders
• History of anticoagulation
• Any known bleeding diathesis
• Any pharmacotherapy in the previous week
• Participants were informed about the prohibition of drinking alcohol, excessive exercise, and stress on the day before blood sampling

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Crystalloid infusion; Intravenous (IV) transfusions were performed of a 20ml/kg of a balanced crystalloid solution (Optilyte®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h	Diagnostic test: Standard laboratory coagulation tests and rotational thromboelastometry measurements; Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results. Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM.
Experimental: Colloid infusion; Intravenous (IV) transfusions were performed of a 20ml/kg of gelatin 26,500 Da (Geloplasma®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h	Diagnostic test: Standard laboratory coagulation tests and rotational thromboelastometry measurements; Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results. Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rotational thromboelastometry (ROTEM) viscoelastic point-of-care coagulation measurements before and after balanced crystalloid infusion	EXTEM, INTEM, FIBTEM assays: A10: clot firmness amplitude measured after 10 minutes (mm); A20: clot firmness amplitude measured after 20minutes (mm); AA: alpha angle (*); CFT: clot forming time (s); CT: clotting time (s); MCE: maximum clot elasticity; MCF: maximum clot firmness (mm); ML: maximum lysis (%)	60 minutes
Rotational thromboelastometry (ROTEM) viscoelastic point-of-care coagulation measurements before and after synthetic colloid infusion	EXTEM, INTEM, FIBTEM assays: A10: clot firmness amplitude measured after 10 minutes (mm); A20: clot firmness amplitude measured after 20minutes (mm); AA: alpha angle (*); CFT: clot forming time (s); CT: clotting time (s); MCE: maximum clot elasticity; MCF: maximum clot firmness (mm); ML: maximum lysis (%)	60 minutes
Standard laboratory tests reporting coagulation status before and after balanced crystalloid infusion	fibrinogen concentration (mg/dl); APTT: activated partial thromboplastin time (s); PT: prothrombin time (s); INR: international normalized ratio; PLT: platelet count (10^3/ul); MPV: mean platelet volume (fl); PDW: platelet distribution width (fl); P-LCR: platelet-large cell ratio (%)	60 minutes
Standard laboratory tests reporting coagulation status before and after synthetic colloid infusion	fibrinogen concentration (mg/dl); APTT: activated partial thromboplastin time (s); PT: prothrombin time (s); INR: international normalized ratio; PLT: platelet count (10^3/ul); MPV: mean platelet volume (fl); PDW: platelet distribution width (fl); P-LCR: platelet-large cell ratio (%)	60 minutes
Standard laboratory tests reporting fibrinolysis status before and after balanced crystalloid infusion	- D-dimer concentration (ug/ml)	60 minutes
Standard laboratory tests reporting fibrinolysis status before and after synthetic colloid infusion	- D-dimer concentration (ug/ml)	60 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety outcomes after crystalloid and colloid infusion	Assessment of safety and potential of adverse events after fluid infusion	28 days

Collaborators and Investigators

• Sponsor: Medical University of Silesia
• Investigators: Study Director: Łukasz J Krzych, Professor, Faculty of Medical Sciences in Katowice, Medical University of Silesia; Principal Investigator: Agnieszka Wiórek, MD, Faculty of Medical Sciences in Katowice, Medical University of Silesia

Publications and helpful links

General Publications

• Wiorek A, Mazur PK, Niemiec B, Krzych LJ. Association between Functional Parameters of Coagulation and Conventional Coagulation Tests in the Setting of Fluid Resuscitation with Balanced Crystalloid or Gelatine: A Secondary Analysis of an In Vivo Prospective Randomized Crossover Study. J Clin Med. 2022 Jul 14;11(14):4065. doi: 10.3390/jcm11144065.

Study record dates

Study Major Dates

• Study Start (Actual): February 16, 2021
• Primary Completion (Anticipated): December 1, 2021
• Study Completion (Anticipated): December 1, 2021

Study Registration Dates

• First Submitted: September 29, 2021
• First Submitted That Met QC Criteria: December 2, 2021
• First Posted (Actual): December 8, 2021

Study Record Updates

• Last Update Posted (Actual): December 8, 2021
• Last Update Submitted That Met QC Criteria: December 2, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: fluid resuscitation; perioperative hemorrhage; fluid therapy; rotational thromboelastometry; goal-directed therapy; dilutional coagulopathy
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Blood Coagulation Disorders; Hemorrhage
• Other Study ID Numbers: KNW/0022/KB1/159/II/15161819

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No